ClinicalTrials.gg
RecruitingNCT06703632MS-PrevecolUpdated Feb 27, 2025

Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection

An interventional study of blood sampling and Survey using a questionnaire. in Screening for Colon Cancer, Blood Samples and Survey and Questionnaire, sponsored by ADVANCED MARKER DISCOVERY S.L.. Recruiting at 2 sites in 2 countries. Open to participants aged 50 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-27.

Primary conditionColonic NeoplasmsRegistry: Colorectal NeoplasmsReclassifiedWhy we changed it
Registry
Colorectal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colonic Neoplasms
Why
  1. The study's listed conditions name Colonic Neoplasms, a narrower term within Colorectal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ADVANCED MARKER DISCOVERY S.L. · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4,538
Allocation
Not applicable
Ages
50 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Colonic Neoplasms with a site in Portugal — 2 open to participants now, 3 under way, 2 of them phase 3. Colonic Neoplasms · Portugal.

Planned enrollment
Largest of 12
4,538 · median 874
Started
2025
the only one that year
No phase
4 of 18
1 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
ADVANCED MARKER DISCOVERY S.L.

Among the 18 studies in Colonic Neoplasms with a site in Portugal, this one has the largest planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 4 with no phase, and was the 18th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

2 of the 18 studies in Colonic Neoplasms with a site in Portugal are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 69 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Colonic Neoplasms with a site in Portugal, or all of them as a file.
02

Study summary

The objective of this low-risk interventional study is to evaluate whether the PreveCol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas when used prospectively in the screening population with a previous positive FOBT result, which could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to be answered are:

  • Values of efficacy, efficiency, impact and safety of PreveCol.
  • Values of preferences of participants for screening methods.
  • Values of PREMs into screening programme.

Participants will provide a blood sample prior to a screening colonoscopy, and complete two questionnaires. They will give their sample, information and clinical data to the investigator or health care personnel.

03

Conditions studied

  • Screening for Colon Cancer
  • Blood Samples
  • Survey and Questionnaire
  • Colorectal Carcinoma
  • Colon Adenocarcinoma
  • Precancerous Lesion of Colon

Browse trials for

Keywords

  • colorectal cancer
  • screening programme
  • liquid biopsy
  • second line
  • questionnaire
04

In context

Colonic Neoplasms Reclassified

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

This study's planned enrollment of 4,538 is above the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.

Browse Colonic Neoplasms studies →

Lead sponsor

ADVANCED MARKER DISCOVERY S.L. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Compared within Colonic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Colorectal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants ages from 50 to 69 years (both included) at the time of signed.
  • Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form.
  • Participants with a positive result of FIT/FOBT analysis referred to the gastroenterology department who are eligible to undertake colonoscopy as a regular procedure of the colorectal cancer screening programme.
  • Participants asymptomatic, average risk for CRC. Average risk is defined as those individuals who are age 50 or over with no history of adenoma, colorectal cancer, or inflammatory bowel disease, and with no family history of CRC (first degree relatives).

Exclusion criteria

Exclusion Criteria:

  • Participants who have developed any another type of cancer in the 5 years prior to their participation in the study.
  • Participants who have previously received chemotherapy or radiotherapy (5 years).
  • Participants previously or currently diagnosed with Familiar Adenomatous Polyposis or Lynch Syndrome or Inflammatory Bowel Disease.
  • Inadequate intestinal preparation for colonoscopy with BBPS score ≤1 in any colon section, excluding diagnostic of CRC.
  • Participants who have undergone polypectomy in the previous 5 years.
  • Hemolysis of blood sample or absence of blood sample.
  • Participants who are arrested at judicial or official request
  • Participants who are in a dependent personal or non-medical relationship with the Sponsor or the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4,538 participants (estimated)

Study arms

  • Other
    PreveCol test after a FOBT positive result

    Average-risk participants from the colorectal cancer screening programme with FOBT positive result who are eligible to undergo colonoscopy

    Diagnostic Test: blood sampling · Other: Survey using a questionnaire.

Interventions

  • Diagnostic testblood sampling

    PreveCol test based on blood sampling

    Also known as: PreveCol

  • OtherSurvey using a questionnaire.

    Preference questionnaire for colorectal cancer screening methods

  • OtherSurvey using a questionnaire.

    PREMs for colorectal cancer screening programme

07

What researchers measure

Primary outcomes

  1. Diagnostic value

    Value of efficiency through the clinical performance (sensitivity, specificity, positive predictive value and negative predictive value) of PreveCol® after FOBT positive result for detecting neoplastic lesions.

    Time frame: 12 months

Secondary outcomes

  1. Diagnostic performance of cancer

    Value of PreveCol's efficiency in second line for detecting cancer

    Time frame: 12 months

  2. Diagnostic performance of lesions

    Value of PreveCol's efficiency in second line for advanced lesions

    Time frame: 12 months

  3. Value of questionnaires into screening programme

    The percentage of number of answers from each preference questions and PREMs

    Time frame: 12 months

Other outcomes

  1. Safety

    Measure the percentage of adverse events and complications directly/indirectly related to interventions of study.

    Time frame: 12 months

08

Study locations

1 of 2 sites recruiting
09

References and documents

Publications

  • Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023 May-Jun;73(3):233-254. doi: 10.3322/caac.21772. Epub 2023 Mar 1. PubMed 36856579 ↗
  • Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth EC; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Oct;33(10):1005-1020. doi: 10.1016/j.annonc.2022.07.004. Epub 2022 Jul 29. No abstract available. PubMed 35914639 ↗
  • Greuter MJE, de Klerk CM, Meijer GA, Dekker E, Coupe VMH. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis. Ann Intern Med. 2017 Oct 17;167(8):544-554. doi: 10.7326/M16-2891. Epub 2017 Oct 3. PubMed 28973514 ↗
  • Bujanda L, Sarasqueta C, Castells A, Pellise M, Cubiella J, Gil I, Cosme A, Arana-Arri E, Mar I, Idigoras I, Portillo I; EUSCOLON Study Investigators. Colorectal cancer in a second round after a negative faecal immunochemical test. Eur J Gastroenterol Hepatol. 2015 Jul;27(7):813-8. doi: 10.1097/MEG.0000000000000366. PubMed 25856688 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Nov 2025, 10 months after the start.

Of 404 interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Nov 25, 2024
StartActual
Jan 14, 2025
Primary completionEst.
Nov 2025
CompletionEst.
Dec 2025
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06703632
Lead sponsor
ADVANCED MARKER DISCOVERY S.L.
Collaborators
Hospital Universitario Ramon y Cajal, Hospital de Santa Maria, Lisbon
Responsible party
Sponsor
First posted
Nov 25, 2024
Start date
Jan 14, 2025
Primary completion
Nov 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Feb 27, 2025

Study contacts

Marta Jimenez, PhD
Contact
mjimenez@amadix.com
+34 637899149
Agustin Albillos, MD
principal investigator · Hospital Universitario Ramon y Cajal
Ana Rita, MD
principal investigator · Hospital de Santa Maria

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion